Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
[2] That work reported a long half-life on the order of 159195 hours (about 78 days) consistent with once-weekly dosing, and it provided the first human safety and tolerability read on the cagrilintide-plus-incretin concept that later became CagriSema
Gastroenterology Research: The BPC-157 and TB-500 combination is evaluated for its interactions with gastrointestinal mucosa and systemic tissue-remodeling pathways
It is injected intramuscularly by a trained health care professional
A retrospective follow-up found that 87% of the participants receiving BPC-157 injections had significant relief of their knee pain that lasted for at least 6 months to a year (length of the follow-up).[ref] A clinical trial in rats found that taking BPC-157 orally in water significantly helped mytendonitis injuries after surgery
Approved injection sites Three areas are standard for subcutaneous injection
